Inhibrx Cancer Treatment Shows High Response Rates In Head And Neck Cancer Study

Large Drugmakers Eye Inhibrx Cancer Drugs Valued Over $8 Billion, Stock Surges

Exclusive: Merck, rivals eye deal for Inhibrx experimental cancer drug tied to Keytruda, sources say

Why Inhibrx's Recent Strength May Not Be Built to Last

Inhibrx shares surge after bone cancer drug slows disease progression in trial

Top 4 Health Care Stocks That Are Preparing To Pump This Month - Inhibrx Biosciences (NASDAQ:INBX)